Business
Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 - CAPR
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Ca...
About this update from Caprock Mining Corp
[{"type":"text","content":"Levi & Korsinsky Reminds Capricor Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 15, 2025 – CAPR\n\n\n\n NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in\n \n Capricor Therapeutics, Inc.\n \n (\"Capricor\" or the \"Company\") (NASDAQ: CAPR) of a class action securities lawsuit.\n \n\n\n CLASS DEFINITION:\n \n The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team:\n \n\n\n https://zlk.com/pslra-1/capricor-therapeutics-inc-lawsuit-submission-form-2?prid=166363&wire=3\n \n\n\n\n CAPR\n \n investors may also contact Joseph E. Levi, Esq. via email at\n \n [email protected]\n \n or by telephone at (212) 363-7500.\n \n\n\n CASE DETAILS:\n \n According to the complaint, defendants provided investors with material information concerning Capricor’s lead cell therapy candidate drug deramiocel for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). Defendants’ statements included, among other things, Capricor’s ability to obtain a Biologics License Application (BLA) for deramiocel from the U.S. Food and Drug Administration (FDA). Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating false and misleading statements and/or concealing material adverse facts concerning its four-year safety and efficacy data from its Phase 2 HOPE-2 trial study of deramiocel. On July 11, 2025, Capricor issued a press release announcing it received a Complete Response Letter (CRL) from the FDA denying the BLA specifically citing it did not meet the statutory requirement for substantial evidence of effectiveness and the need for additional clinical data. Further, the CRL referenced outstanding items in the Chemistry, Manufacturing, and Controls section of the application. Following this news, the price of Capricor stock declined from $11.40 per share on July 10, 2025 to $7.64 per share on July 11, 2025.\n \n\n\n WHAT'S NEXT?\n \n If you suffered a loss in Capricor during the relevant time frame, you have until\n \n September 15, 2025\n \n to request that the...